Kailera Therapeutics Raises $600 Million Series B to Advance Obesity Drug Pipeline
Kailera Therapeutics, a clinical-stage biopharmaceutical company focused on obesity treatments, has raised $600 million in a Series B financing round to accelerate development of its advanced pipeline.
The round was led by Bain Capital Private Equity, and included participation from both new and existing investors such as Adage Capital Management, Canada Pension Plan Investment Board (CPP Investments), Invus, Janus Henderson Investors, Perseverance Capital, Qatar Investment Authority, Royalty Pharma, Surveyor Capital (a Citadel company), and accounts advised by T. Rowe Price Associates. Returning backers also included Atlas Venture, Bain Capital Life Sciences, RTW Investments, and Sirona Capital.
The financing will fully fund Kailera’s next steps, notably enabling the company to launch a global Phase 3 program for its lead candidate, KAI-9531, by year-end. KAI-9531 is an injectable dual GLP-1/GIP receptor agonist that the company believes may deliver best-in-class weight loss. Kailera completed its End-of-Phase 2 meetings with the U.S. Food and Drug Administration and is targeting two Phase 3 trials in adults with obesity or overweight—with and without type 2 diabetes—as well as a third trial in individuals with a BMI of 35 or higher.
Beyond KAI-9531, the newly raised capital will support other pipeline candidates, including KAI-7535, an oral small-molecule GLP-1 receptor agonist; an oral tablet formulation of KAI-9531; and KAI-4729, an injectable tri-agonist that targets GLP-1, GIP, and glucagon receptors. These programs reflect Kailera’s strategy of offering differentiated therapies across both injectable and oral modalities, helping to address diverse needs in chronic weight management.
Kailera originally launched in 2024 with a massive $400 million Series A round co-led by Atlas Venture, Bain Capital Life Sciences, and RTW Investments, with participation from Lyra Capital. At that time, Kailera acquired global rights (outside of Greater China) to a suite of metabolic disease assets licensed from Jiangsu Hengrui Pharmaceuticals.
The company is based in Waltham, Massachusetts, with operations also in San Diego, and is driven by a mission to develop next-generation weight management therapies that transform lives. Kailera’s pipeline reflects a commitment to both scientific innovation and clinical rigor, leveraging Hengrui-licensed assets that have already demonstrated encouraging data in China.
Kailera’s Series B comes amid a broader surge of investor interest in obesity therapeutics, especially companies developing GLP-1 and dual-agonist treatments. The funding round not only reflects confidence in KAI-9531’s potential but also in Kailera’s diversified strategy and global ambitions. With this level of capital, Kailera is well positioned to advance multiple programs, scale its clinical operations, and emerge as a serious contender in the obesity treatment space.
